Recon: Makers report Tamiflu shortage; Groups ask US Supreme Court to review pelvic mesh cases

• Several manufacturers report Tamiflu shortage as flu season reaches high point (Endpoints News)
• Biotech M&A, is picking back up. Here are the latest deals. (Biopharma Dive)
• FDA and EMA accept Pfizer’s regulatory submissions for ulcerative colitis drug (Endpoints News)
• WLF, AdvaMed Ask Supreme Court To Review Pelvic Mesh Litigation (MedTech Insight)
• Click wins FDA breakthrough designation for prescription digital migraine therapy (MedTech Dive)

• European Regulatory Roundup, December 2022: Repositioning The MDR For A Better Year In 2023 (MedTech Insight)
• EU Guidance On Periodic Safety Update Reports: Mixed Reactions (MedTech Insight)
• UK CMA Launches Inquiry Into Steep Antibiotics Price Rise (Generics Bulletin)
• MHRA Wins £168k Funding Grant For AI Medtech Integration Project (MedTech Insight)
• Challenges Remain For Off-Patent Industry’s COVID Response (Generics Bulletin)
• UK Regulator Gets Funding For Clinical Trials With ‘Artificial Patients’ (Pink Sheet)
• Industry Breathes Sigh Of Relief Over UK Batch Release Move (Generics Bulletin)

• Pfizer Doubles Down on AI/ML to Bring Transformative Medicines to Patients (Biospace)
• Two Biotech CEOs Charged in Securities Fraud Schemes (Biospace)
• Trends for 2023: What's coming next in pharma marketing and drug commercialization? (Endpoints News)
• European regulators back hemophilia gene therapy (Biopharma Dive)
• Roche takes over development of Biogen-partnered lymphoma drug (Biopharma Dive)
• For ALS patients, doctors, a new medicine reignites concerns about healthcare access (Biopharma Dive)
• AbbVie: ‘We Looked At Biosimilars, We Are Not Interested’ (Generics Bulletin)
• BioNTech doses first patient in herpes vaccine candidate clinical trial (Reuters)
• BioNtech ready to ship first mRNA vaccine factory kit to Africa (Reuters)
• Vistagen buys out Pherin more than 4 years after licensing now-lead social anxiety spray (Fierce Biotech)

• Dexcom’s Jake Leach discusses preparations for G7 launch next year (MedTech Dive)
• Philips says tests on recalled products show limited health risks (Reuters)
• Quris reels in $9M in seed funding to support AI innovations in trials (Fierce Biotech)
• 2023 forecast: A closed loop of upgraded sensors and algorithms could 'put diabetes in the background' (Fierce Biotech)

• Interchangeable Biosimilars May Qualify For ‘Immediate Substitution’ In Medicare Part D (Generics Bulletin)  
• Can a Federally Funded ‘Netflix Model’ Fix the Broken Market for Antibiotics? (New York Times)